期刊
NATURE MEDICINE
卷 17, 期 1, 页码 123-U302出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.2269
关键词
-
资金
- US National Institutes of Health [U24 CA92871, P01 CA104177]
- Society of Nuclear Medicine
- Korea Science and Engineering Foundation
- US National Foundation for Cancer Research
- NATIONAL CANCER INSTITUTE [P01CA104177, R01CA127641, U24CA092871, R01CA097318] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH093195] Funding Source: NIH RePORTER
Molecular-genetic imaging is advancing from a valuable preclinical tool to a guide for patient management. The strategy involves pairing an imaging reporter gene with a complementary imaging agent in a system that can be used to measure gene expression or protein interaction or track gene-tagged cells in vivo. Tissue-specific promoters can be used to delineate gene expression in certain tissues, particularly when coupled with an appropriate amplification mechanism. Here we show that the progression elevated gene-3 (PEG-3) promoter, derived from a rodent gene mediating tumor progression and metastatic phenotypes, can be used to drive imaging reporters selectively to enable detection of micrometastatic disease in mouse models of human melanoma and breast cancer using bioluminescence and radionuclide-based molecular imaging techniques. Because of its strong promoter activity, tumor specificity and capacity for clinical translation, PEG-3 promoter-driven gene expression may represent a practical, new system for facilitating cancer imaging and therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据